News
Exonate has announced plans to initiate a phase 2b clinical trial of its lead candidate EXN407, a topical SRPK1 inhibitor, ...
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical ...
Statistical analysis showed a strong association between advanced diabetic retinopathy and an increased likelihood of heart ...
Diabetic retinopathy is a common complication of diabetes, which manifests as a potentially severe eye disease that can lead ...
EHR-Based Survival Models Accurately Predict Progression to Proliferative Diabetic Retinopathy: JAMA
USA: A new study has found that survival models using electronic health record (EHR) data can accurately predict the ...
1don MSN
Researchers at Edith Cowan University (ECU) have developed a cutting-edge Artificial Intelligence (AI) system that could ...
Danegaptide, a potential oral therapy for nonproliferative diabetic retinopathy, is advancing to a phase 2 trial after ...
India, often labelled the diabetic capital of the world, faces an alarming crisis with over 77 million people diagnosed with ...
Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...
Doctors in India are constantly raising alarms over the rise in cases of vision loss among those battling type 2 ...
A large, prospective study implicates high levels of interleukin 6 with severity of diabetic retinopathy and shows it may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results